ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024
Annual Meeting of Stockholders will be held on Tuesday, June 11,
2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in
a virtual-only format and there will not be a physical location for
the Annual Meeting. Stockholders of record at the close of business
on April 17, 2024 are entitled to vote at and participate in the
Annual Meeting.
Richard Adcock, the Company’s Chief Executive Officer and
President, will provide a business update after the formal business
of the Annual Meeting has ended. All interested parties are welcome
to attend the Annual Meeting and listen to the Company update.
Non-stockholders can attend the virtual Annual Meeting by using the
following link: virtualshareholdermeeting.com/IBRX2024 and clicking
on the “GUEST” button to join the meeting. This website will
available 15 minutes prior to the start of the Annual Meeting.
A playback of this event will be available for replay within 24
hours after the completion of the Annual Meeting at
ir.immunitybio.com/ for at least 90 days after the event.
Availability of Other Information about ImmunityBio,
Inc.
A playback of this event, along with other selected webcasts and
presentations regarding developments in the Company’s business
given by management at certain investor and medical conferences,
can be found on the Company’s Investor Relations website,
ir.immunitybio.com, under “CompanyꟷEvents & Presentations.” The
information posted on this website could be deemed to be material
information. As a result, investors, the media, and others
interested in ImmunityBio are encouraged to review this information
on a regular basis. The contents of the Company’s websites, or any
other website that may be accessed from the Company’s website,
shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended.
About ImmunityBio
ImmunityBio is a vertically-integrated biotechnology company
developing next-generation therapies and vaccines that bolster the
natural immune system to defeat cancers and infectious diseases.
The company’s range of immunotherapy and cell therapy platforms,
alone and together, act to drive and sustain an immune response
with the goal of creating durable and safe protection against
disease. Designated an FDA Breakthrough Therapy, ANKTIVA® is the
first FDA-approved immunotherapy for non-muscle invasive bladder
cancer that activates natural killer cells, T cells, and memory T
cells for a long duration response. The company is applying its
science and platforms to treating cancers, including the
development of potential cancer vaccines, as well as developing
immunotherapies and cell therapies that we believe sharply reduce
or eliminate the need for standard high-dose chemotherapy. These
platforms and their associated product candidates are designed to
be more effective, accessible, and easily administered than current
standards of care in oncology and infectious diseases.
For more information, please visit: www.immunitybio.com
Forward-Looking Statements
This press release and the event referenced herein may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, such as statements
regarding anticipated event timing and content, data and results
from clinical trials and potential implications therefrom,
commercialization plans and timelines, including product
availability and shipments, potential regulatory pathways and
approval requests and submissions, FDA meetings, timelines and
potential results therefrom, the regulatory review process and
timing thereof, market and prevalence data, potential benefits to
patients, potential treatment outcomes for patients, the described
mechanism of action and results and contributions therefrom,
information regarding ongoing pre-clinical studies and clinical
trials, potential future uses and applications of ANKTIVA and use
in cancer vaccines and across multiple tumor types, ImmunityBio’s
financial condition, and ImmunityBio’s approved product and
investigational agents as compared to existing treatment options,
among others. Statements in this presentation that are not
statements of historical fact are considered forward-looking
statements, which are usually identified by the use of words such
as “anticipates,” “believes,” “continues,” “goal,” “could,”
“estimates,” “scheduled,” “expects,” “intends,” “may,” “plans,”
“potential,” “predicts,” “indicate,” “projects,” “seeks,” “should,”
“will,” “strategy,” and variations of such words or similar
expressions. Statements of past performance, efforts, or results of
our preclinical and clinical trials, about which inferences or
assumptions may be made, can also be forward-looking statements and
are not indicative of future performance or results.
Forward-looking statements are neither forecasts, promises nor
guarantees, and are based on the current beliefs of ImmunityBio’s
management as well as assumptions made by and information currently
available to ImmunityBio. Such information may be limited or
incomplete, and ImmunityBio’s statements should not be read to
indicate that it has conducted a thorough inquiry into, or review
of, all potentially available relevant information. Such statements
reflect the current views of ImmunityBio with respect to future
events and are subject to known and unknown risks, including
business, regulatory, economic and competitive risks,
uncertainties, contingencies and assumptions about ImmunityBio,
including, without limitation, (i) the risks and uncertainties
associated with commercial launch execution, success and timing,
(ii) risks and uncertainties related to the regulatory submission
and review process, (iii) the ability of ImmunityBio to continue
its planned preclinical and clinical development of its development
programs through itself and/or its investigators, and the timing
and success of any such continued preclinical and clinical
development, patient enrollment and planned regulatory submissions,
(iv) potential delays in product availability and regulatory
approvals, (v) risks and uncertainties associated with third party
collaborations and agreements, (vi) whether the BCG manufactured by
Serum Institute of India will receive regulatory approval in the
U.S. and/or other regions, (vii) ImmunityBio’s ability to retain
and hire key personnel, (viii) ImmunityBio’s ability to obtain
additional financing to fund its operations and complete the
development and commercialization of its various product
candidates, (ix) potential product shortages or manufacturing
disruptions that may impact the availability and timing of product,
(x) ImmunityBio’s ability to successfully commercialize its
approved product and product candidates and uncertainties around
regulatory reviews and approvals, (xi) ImmunityBio’s ability to
scale its manufacturing and commercial supply operations for its
approved product and future approved products, and (xii)
ImmunityBio’s ability to obtain, maintain, protect and enforce
patent protection and other proprietary rights for its product
candidates and technologies. More details about these and other
risks that may impact ImmunityBio’s business are described under
the heading “Risk Factors” in the Company’s Form 10-K filed with
the U.S. Securities and Exchange Commission (“SEC”) on March 19,
2024 and the Company’s Form 10-Q filed with the SEC on May 9, 2024,
and in subsequent filings made by ImmunityBio with the SEC, which
are available on the SEC’s website at www.sec.gov. ImmunityBio
cautions you not to place undue reliance on any forward-looking
statements, which speak only as of the date hereof. ImmunityBio
does not undertake any duty to update any forward-looking statement
or other information in this press release, except to the extent
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240607246847/en/
Investors Hemanth Ramaprakash, PhD, MBA
ImmunityBio, Inc. +1 858-746-9289
Hemanth.Ramaprakash@ImmunityBio.com
Media Greg Tenor Salutem +1 717-919-6794
Gregory.Tenor@Salutemcomms.com
ImmunityBio (NASDAQ:IBRX)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
ImmunityBio (NASDAQ:IBRX)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025